Acadia Pharmaceuticals CEO Catherine Owen Adams breaks down the company’s recent rebrand, its expansion into rare disease marketing and how it’s using AI.

Neurocrine Biosciences shows strong growth with rising INGREZZA sales, expanding pipeline, and solid financials despite key ...

Having already established a commercial infrastructure for its oral hereditary angioedema (HAE) drug Orladeyo and eager to ...

Alert systems, also known as trigger-based systems, provide a critical advantage over raw data delivery approaches by ...

Scientists do not fully understand what causes the chronic neurodegenerative disease Alzheimer's, but they are examining a ...

Adaptive Biotechnologies (“we” or “our”) is a commercial-stage biotechnology company focused on harnessing the inheent biology of the adaptive immune system to transform the diagnosis and treatment of ...

Preliminary results from a small trial offer the clearest evidence yet that the brain disease’s progression can be slowed. A one-time gene therapy can markedly slow the progression of Huntington’s ...

In a year where avian influenza, measles and legionnaire’s disease have taken the spotlight, the Centers for Disease Control and Prevention is saying that a parasitic infection caused by a “kissing ...